Cargando…
Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
Prostate cancer is the second leading cause of cancer death in men in the US and Europe. The treatment of advanced-stage prostate cancer has been androgen deprivation. Medical castration leads to decreased production of testosterone and dihydrotestosterone by the testes, but adrenal glands and even...
Autores principales: | Rehman, Yasser, Rosenberg, Jonathan E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267518/ https://www.ncbi.nlm.nih.gov/pubmed/22291466 http://dx.doi.org/10.2147/DDDT.S15850 |
Ejemplares similares
-
Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
por: Harshman, Lauren C., et al.
Publicado: (2013) -
Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
por: Linden-Castro, Edgar, et al.
Publicado: (2014) -
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023) -
Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
por: Nagai, Takashi, et al.
Publicado: (2018) -
Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2018)